Creative Biolabs is a contract research organization specialized in offering customized services for the development of antibodies for use in diagnostics, drug discovery, and basic research. Especially, we provide the expertise and personnel to offer high-quality in vitro diagnostic (IVD) antibody development services targeting a wide range of high-value diagnostic biomarkers to our clients. Here, we introduce our IVD antibody development services for Chac1 marker.
Glutathione Specific Gamma-glutamylcyclotransferase 1 (Chac1)
Glutathione specific gamma-glutamylcyclotransferase 1 (Chac1) is a member of the gamma-glutamylcyclotransferase family of proteins. Acting as a negative regulator of Notch signaling pathway, it can inhibit deglycination of the Notch receptor, resulting in an immature inactive receptor, thereby suppressing Notch signaling pathway which is involved in embryonic neurogenesis. Besides, Chac1 plays a role in the regulation of glutathione levels. It can catalyze the cleavage of glutathione into 5-oxo-L-proline and a Cys-Gly dipeptide thereby decrease glutathione levels. While the degradation of glutathione plays a role in the regulation of cells apoptosis initiation and execution. This suggests that Chac1 may be a pro-apoptotic component regulating cells apoptosis. And the result has been revealed that chac1 may be regarded as an independent indicator for prediction of cancer risk. Increasing chac1 levels is associated with the elevated risk of breast and ovarian cancer.
Fig. 1 The structure and topology of gamma-glutamylcyclotransferase 1. (Oakley A J., 2008)
Chac1 Marker of Acute Kidney Injury (AKI)
Recent studies have been shown that chac1 may be a novel biomarker for early diagnosis of AKI. Although the mechanism of action of chac1 still remains incompletely understood in the progression of AKI, the expression of chac1 significantly increase in the early phase after AKI, and subsequently down to baseline levels within 30 to 70 hours, preferred 40 to 60 hours, especially preferred 48 hours of the event. It is also reported that chac1 levels strongly elevate 6 h after ischemia reperfusion injury. However, a significant drop in expression levels as early as 24 h after injury. Similarly, before surgery chac1 cannot be detected in the urine, but as early as 2 hours postoperatively and eliminates quickly after acute kidney injury. Hence, Chac1 is a highly specific indicator for the early diagnosis of acute kidney injury, which will help to specifically identify an acutely injured kidney.
Fig.2 Western blot analysis of urinary Chac1 in the renal ischemia-reperfusion injury. (Halbeisen P., 2017)
IVD Antibody Development Services for Chac1 Marker
IVD antibodies are essential elements of commercial antibody-based in vitro diagnostic kits. Creative Biolabs has built an IVD platform for not only the development of high-quality antibodies for diagnostic use but also antibody & antigen conjugation and IVD kit development. Thus, we can help develop polyclonal, monoclonal, and recombinant antibodies against Chac1 to aid in the development of IVD kits based on different immunoassay formats, such as latex-enhanced immunoturbidimetry, lateral flow immunochromatographic assays, and ELISA.
Supported by our highly specialized scientists and advanced platform, we are confident in providing services with the best quality and the most competitive prices. If you are interested in our services, contact us for more information.
References
For Research Use Only.
